Jul 05, 2024 4:01 pm EDT Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jul 03, 2024 7:57 pm EDT Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum
Jun 21, 2024 4:01 pm EDT Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases
Jun 07, 2024 4:01 pm EDT Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jun 05, 2024 4:01 pm EDT Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
May 29, 2024 4:01 pm EDT Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
May 20, 2024 9:25 am EDT Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
May 09, 2024 4:01 pm EDT Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress
May 03, 2024 4:01 pm EDT Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)